Altamont Pharma Acquisition in a letter to the SEC said it was withdrawing a planned offering of 10 million units registered in AMarch 2021.
The SPAC had said it would target companies engaged in healthcare innovation.
The company is led by President, CEO and Chairman Mark Pearson, founder and CEO of biotech investment firm Altamont Pharma.
The SPAC had applied for a Nasdaq listing, with Chardan tapped as sole book-running manager. Read more.
